Johnson & Johnson coronavirus vaccine wins FDA authorisation

The big pharmaceutical company's jab has some important advantages.

| More on:
coronavirus vaccine represented by gloved hand drawing down from syringe

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The United States now has a third coronavirus vaccine authorised for use. Johnson & Johnson (NYSE: JNJ)'s vaccine, developed by its subsidiary Janssen, received Emergency Use Authorisation (EUA) from the FDA on Saturday. This followed a unanimous vote by the regulator's vaccines and related biological products advisory committee that it do so.

In contrast to the two shots required for both of the other FDA-authorised coronavirus vaccines -- Moderna Inc (NASDAQ: MRNA)'s mRNA-1273 and Pfizer Inc (NYSE: PFE) and BioNTech (NASDAQ: BNTX)'s BNT162b2 -- Johnson & Johnson's is a one-shot inoculation. 

It also has relatively less burdensome storage requirements, as it can be kept for as long as three months in standard refrigeration temperatures of 36 to 46 degrees Fahrenheit.

The Johnson & Johnson vaccine demonstrated notably lower efficacy (72%) in late-stage testing compared the 95% or so of its two peers. However, 72% is still considered unusually high by vaccine development standards, plus Johnson & Johnson's was shown to be 100% efficacious in preventing hospitalisation and death. 

The Moderna and Pfizer/BioNTech shots were authorised in December and so far have been administered to nearly 15% of the US population. So it's likely that Johnson & Johnson's jab won't lap past them, no matter its advantages. It will, however, help push the inoculation rate up quickly.

Investors should be aware that Johnson & Johnson won't be making money from the vaccine during the pandemic. As it reiterated in the press release trumpeting the EUA, it will provide the jab "on a not-for-profit basis for emergency pandemic use."

The company added that it has already started to ship the vaccine, with the goal of delivering enough to inoculate over 20 million people in the US by the end of March. 100 million doses should be shipped by the end of June.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Johnson & Johnson and Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

Modern accountant woman in a light business suit in modern green office with documents and laptop.
International Stock News

Which Magnificent 7 company I expect to suprise the market this earnings season

I can't wait to see what this stock has to say next week.

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
International Stock News

Could buying Amazon stock today set you up for life?

Amazon has several growth drivers, with AI being an incredible opportunity.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Will Nvidia announce something big on July 16?

Nvidia has been an artificial intelligence leader and major winner over the past few years.

Read more »

Four red apples in the air.
International Stock News

Why Apple fell 18.1% in the first half of 2025

Apple came into the year at a high valuation.

Read more »

A woman sits in front of a computer and does some calculations.
International Stock News

It's official — Nvidia hit a $4 trillion valuation. Here is the next "Magnificent Seven" stock I think will hit a historical milestone this year.

Nvidia recently became the world's first $4 trillion company, but one of its megacap peers is knocking on the door…

Read more »

Woman and man calculating a dividend yield.
International Stock News

US earnings kicks off this week: What I'm watching

ASX investors should get the popcorn out for this US earnings season.

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
International Stock News

Prediction: This will be the next $4 trillion-dollar stock

Read on to find out why.

Read more »

A woman in jeans and a casual jumper leans on her car and looks seriously at her mobile phone while her vehicle is charged at an electic vehicle recharging station.
International Stock News

Prediction: Tesla might lose this $2.76 billion revenue source that is nearly 100% profit

This challenge could swiftly eliminate one of Tesla's most profitable revenue sources.

Read more »